Pharmaceuticals
News Category
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech announced the appointment of Dr. Christoph Erkel as Chief Scientific Officer, bringing extensive experience in antibody therapeutics to...
NanoViricides Raises $3.8 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug Pipeline
NanoViricides secured $3.8 million through a registered direct offering with a single institutional investor, providing capital to advance its lead an...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG appointed Christoph Erkel as Chief Scientific Officer to lead the development of its BiTAC platform for solid tumor cancer therapies...
VERAXA Biotech Advances BiTAC-TCE Development with Positive Regulatory Feedback from Germany
VERAXA Biotech received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE program, reducing development uncertainty bef...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity for non-clinical deve...
Siegfried Appoints Eduardo Montanha as Chief Operating Officer to Drive Integrated Operations Strategy
Siegfried has appointed Eduardo Montanha as COO, effective September 1, 2026, to lead the newly combined Drug Substances and Drug Products operations,...
NextPlat Corp Expands PharmcoRx With Planned Florida Pharmacy Acquisition
NextPlat Corp announced an agreement to acquire an independent pharmacy in rural Florida, expanding its PharmcoRx network and targeting underserved ma...
Onco-Innovations Completes Analytical Reference Standard Program for ONC010, Advancing CMC Framework
Onco-Innovations Limited announced the completion of its analytical reference standard preparation program for ONC010, a key step in strengthening its...
VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with ATUM Cell Line Development Partnership
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program in partnership with ATUM, marking a critical step toward ...
Sustained Release Polymers Market to Reach USD 7.8 Billion by 2036, Driven by Chronic Disease Management and Drug Delivery Innovation
The global sustained release polymers market is projected to grow at a CAGR of 7.4% from 2026 to 2036, driven by increasing chronic disease prevalence...
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy, Targeting IND by 2028
VERAXA Biotech provided a corporate update highlighting progress in its BiTAC platform and increasing pharmaceutical interest, aiming to advance lead ...
VERAXA Biotech Initiates Cell Line Development for BiTAC Cancer Therapy, Aiming to Improve Tumor Selectivity
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, following encouraging prec...
Why VERAXA Biotech AG Shareholders Should Monitor Antibody Therapeutics Sector Deals
The article highlights the importance of early-stage partnerships and licensing deals in antibody therapeutics, particularly ADCs and T-cell engagers,...
Ace Therapeutics Unveils Comprehensive Preclinical Analgesic Drug Development Services with Full-Spectrum Pain Research Platform
Ace Therapeutics announces end-to-end preclinical services for analgesic drug development, featuring diverse in vivo pain models and a complete suite ...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve profitability, affecting 32 employees, as ...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Extraction and Integrated Drug Manufacturing Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics announced the full repayment of its $60 million revolving credit facility, funded by strong operational cash flow, highlighting th...
Voyageur Pharmaceuticals Narrows Down Three U.S. Sites for Integrated Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals evaluates three U.S. sites in Oklahoma and Texas for its vertically integrated iodine and barium contrast media manufacturing...
Earth Science Tech Inc. (ETST) Poised to Capitalize on Telemedicine and Pharmacy Integration
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, positioning...
Voyageur Pharmaceuticals Submits Multi-Year Permit Application for Bulk Sampling at Frances Creek Barite Project
Voyageur Pharmaceuticals has applied for a five-year advanced exploration permit to bulk sample barite and conduct feasibility studies at its Frances ...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Contrast Media Development
Voyageur Pharmaceuticals has closed a $5 million non-brokered private placement under the Listed Issuer Financing Exemption, with proceeds allocated t...
Kairos Pharma Expands Pipeline with CL-741 Acquisition, Reports Clinical Progress in Mid-Year Update
Kairos Pharma announced plans to acquire worldwide rights to Phase 1-ready oral c-MET inhibitor CL-741, complementing its oncology pipeline, and repor...
Quantum BioPharma Showcases Lucid-MS and unbuzzd(TM) Potential on BioMedWire Podcast
Quantum BioPharma’s lead drug candidate Lucid-MS addresses an unmet need in multiple sclerosis by targeting nerve damage, while its commercial product...
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Multiple Sclerosis Program and Diversifies Portfolio
Quantum BioPharma is a clinical-stage biopharmaceutical company with a differentiated multiple sclerosis program targeting demyelination, a strong pip...
Redwood AI Gains DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp. announces DTC eligibility to simplify U.S. trading and liquidity, and engages InvestorBrandNetwork for a market awareness campaign th...
Carmed Pharmaceuticals Gains CityBiz Coverage as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is featured in a CityBiz executive Q&A as it...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Discovery
Sino Biological's new XPressMAX™ kit enables ultra-fast, high-throughput cell-free protein synthesis in just 3 hours, supporting AI-driven screening f...
NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox
NanoViricides reported progress on NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug designation for measl...
NanoViricides Prices $2 Million Registered Direct Offering
NanoViricides announced a $2 million registered direct offering to an institutional investor, issuing common shares and warrants, with proceeds expect...
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Precision Oncology Pipeline
Lantern Pharma closed a $4.4 million registered direct offering, providing capital to support its clinical pipeline and AI platform, underscoring its ...
Tonix Pharmaceuticals to Present at Two Major Investor Conferences in May
Tonix Pharmaceuticals announced its participation in two upcoming investor conferences, highlighting its commercial-stage biotechnology focus on CNS a...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model, providing a real-time web-based molecular intellige...
LIXTE Biotechnology’s LB-100 Emerges as Novel Enhancer of Cancer Therapies, Targeting Solid Tumors with Unmet Needs
LIXTE Biotechnology’s first-in-class PP2A inhibitor LB-100 is advancing through multiple clinical trials as a potential enhancer of chemotherapy and i...
Soligenix Showcased for Smart Platform-Based Drug Development Strategy
Soligenix exemplifies efficient drug development by leveraging synthetic hypericin across multiple dermatologic indications, reducing redundancy and e...
PolyPeptide Shareholders Approve All Proposals at 2026 Annual General Meeting
At PolyPeptide's fifth AGM, shareholders approved all board proposals, including re-election of directors and auditors, reflecting strong governance a...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlighting Transformational Year with Clinical Progress and Strategic Expansion
LIXTE Biotechnology Holdings announced its 2025 annual results, detailing leadership changes, advancement of its lead compound LB-100, acquisition of ...
LIXTE Biotechnology's PP2A Inhibitor LB-100 Poised to Improve Cancer Treatment Outcomes
LIXTE Biotechnology holds the world's only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to therapies and disrupts can...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates Stephen Fry, former Eli Lilly executive, to its Board of Directors, bringing deep pharma industry experience and expertise in organiza...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects, Targets FDA Approval and Vertically Integrated Supply Chain
Voyageur Pharmaceuticals is progressing its barium and iodine contrast media projects, aiming to establish a vertically integrated North American supp...
Soligenix Secures European Orphan Drug Designation for Dusquetide in Behcet's Disease
The EMA's positive opinion for orphan drug designation of dusquetide in Behcet's disease provides development incentives and potential market exclusiv...
Netherton Syndrome Awareness Campaign Surpasses 2 Million Video Views, Highlighting Urgent Need for Treatments
Quoin Pharmaceuticals' NETHERTON NOW campaign has generated 2 million video views and 24 million impressions, underscoring growing global awareness of...
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on Late-Stage Biotech M&A Trends
Oncotelic Therapeutics was featured in a BioMedWire editorial discussing the increasing M&A focus on late-stage clinical assets, positioning its OT-10...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced publication of Phase 2a trial results in Nature Medicine showing a single dose of SPL026 significantly reduced depressive sympt...
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys announces positive Phase 2 results for MVP-S combination therapy in metastatic bladder cancer, showing objective responses including in check...
Quantumzyme Corp. Announces 2025 Progress, AI Focus, and Plans for Name Change to Quantum Genesis AI Corp.
Quantumzyme Corp., a biotransformation company, reported its 2025 achievements including AI integration in enzyme research, and outlined 2026 prioriti...
Creative Biolabs Upgrades Biosimilar Development Platform
Creative Biolabs enhances its end-to-end biosimilar development and CDMO platform, offering advanced physicochemical characterization, biological acti...
Protheragen Unveils Integrated Drug Analysis Solutions for Enhanced Quality Assurance
Protheragen's comprehensive drug analysis services, including stability studies, impurity testing, and chemical-physical testing, aim to streamline ph...